Phase I clinical study to evaluate safety, tolerance and pharmacokinetics of SY-007 after single-dose incremental intravenous injection in healthy subjects
Latest Information Update: 07 May 2021
At a glance
- Drugs K 13 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Yabao Pharmaceutical Group
Most Recent Events
- 30 Apr 2021 Status changed from recruiting to completed.
- 16 Mar 2020 Planned End Date changed from 30 Apr 2020 to 31 Dec 2020.
- 16 Mar 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Jul 2020.